Avadel Pharmaceuticals PLC (AVDL) Key Ratios
$21.64
$0.00 (0.00%)As on 13-Feb-2026 09:30EDT
Market cap
$2,124 Mln
Revenue (TTM)
$249 Mln
P/E Ratio
--
P/B Ratio
21.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 13.71 | 54.86 | 79.88 | -- | 39.20 |
| EBIT | -72.10 | 772.44 | 110.33 | 27.37 | -8.73 |
| Net Profit | -99.79 | 100.76 | 99.62 | 25.95 | -144.48 |
| EPS | -99.80 | 100.72 | 99.31 | 25.94 | -151.91 |
| Book Value | -- | -- | -24.97 | -16.90 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-24 | Dec-23 |
| EBIT-Margin
| -2,395.45 | -1,787.73 | 2.60 | -22.62 | -539.61 |
| Net Margin
| -- | -1,801.97 | -0.11 | -- | -- |
| Return on equity
| -341.10 | -215.41 | -0.32 | -60.44 | -481.35 |
| Return on Capital
| -100.49 | -65.57 | -- | -58.86 | -160.08 |
| Return on Assets
| -69.93 | -46.88 | -0.12 | -29.69 | -107.75 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.02 | 0.03 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
--
|
-58.86
|
-160.08
|
-82.53
|
-29.97
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-0.32
Lower than Peers by 19.29
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
-0.32
|
-60.44
|
-481.35
|
-481.49
|
-64.30
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
-0.12
Lower than Peers by 2.98
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
-0.12
|
-29.69
|
-107.75
|
-72.34
|
-27.67
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
2.60
Lower than Peers by 13.22
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
2.60
|
-22.62
|
-539.61
|
-6,624.13
|
--
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
-0.11
Lower than Peers by 8.34
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
-0.11
|
-28.87
|
-573.17
|
-9,188.77
|
-3,637.30
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
79.88
Higher than Peers by 71.82
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
79.88
|
5.05
|
17.69
|
--
|
-1.00
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
110.33
Higher than Peers by 102.06
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
110.33
|
74.65
|
-52.27
|
-19.10
|
-1,151.61
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
99.62
Higher than Peers by 91.89
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
99.62
|
69.53
|
-16.59
|
-77.77
|
-1,200.30
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
99.31
Higher than Peers by 88.92
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
99.31
|
0.73
|
0.14
|
-0.65
|
-11.95
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
25.09
Higher than Peers by 20.22
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
25.09
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
--
|
0.02
|
0.03
|
-6.20
|
1.85
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
0.01
|
0.01
|
0.01
|
-1.83
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.76
Higher than Peers by 1.11
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
2.76
|
2.75
|
3.64
|
1.81
|
9.17
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
2.37
Higher than Peers by 1.17
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
2.37
|
2.33
|
3.36
|
1.81
|
--
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
0.66
Lower than Peers by 4.10
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
0.66
|
-3.53
|
-15.26
|
-8.03
|
-8.37
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
17.08
Lower than Peers by 4.19
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
17.08
|
20.16
|
43.28
|
150.27
|
--
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
1.07
Higher than Peers by 0.67
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
1.07
|
1.03
|
0.19
|
0.01
|
--
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
--
|
49.89
|
93.73
|
4,124.69
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
--
|
366.73
|
2,240.72
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
--
|
224.27
|
4,171.23
|
1,904.41
|
2,378.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
--
|
192.35
|
-1,836.79
|
2,220.28
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
--
|
-20.75
|
-7.57
|
-3.29
|
-6.13
|
|
Peer Median
|
37.91
|
--
|
--
|
--
|
--
|
Price / Book Value
21.62
Higher than Peers by 13.93
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
21.62
|
13.72
|
13.83
|
-21.41
|
6.05
|
|
Peer Median
|
7.69
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.56
|
--
|
--
|
--
|
--
|
EV/EBITDA
200.89
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
200.89
|
-26.46
|
-7.45
|
-4.99
|
-5.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
2,124
Lower than Peers by 397
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-24
|
Dec-23
|
Dec-22
|
Dec-21
|
|---|---|---|---|---|---|
|
Avadel Pharmaceuticals PLC (AVDL)
|
2,124
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,521
|
--
|
--
|
--
|
--
|